Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 18:50 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma
NCT04604132 · Basilea Pharmaceutica · PHASE1/PHASE2 · terminated · last registry update 2024-04-04 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Terminated prematurely for administrative reasons not related to patient safety.” | – | Registry record, Basilea Pharmaceutica |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FGFR3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-03-25Results posted on the registry: H. Lee Moffitt Cancer Center and Research Institute, Nivolumab + Ipilimumab (NCT03377023)
- 2025-03-12Phase 3 first posted: QED Therapeutics, a BridgeBio company, infigratinib 0.128 mg/kg/day + infigratinib 0.25 mg/kg/day (NCT06873035)
- 2025-03-06Also stopped (terminated): Boehringer Ingelheim, BIBF 1120 M + Pemetrexed + BIBF 1120 H + Pemetrexed (NCT00979576)
- 2025-02-24Results posted on the registry: Janssen Research & Development, LLC, Erdafitinib (NCT04083976)
- 2025-02-24Also stopped (withdrawn): West Virginia University, Nintedanib + Placebo (NCT05067517)
- 2025-02-13Also stopped (terminated): Boehringer Ingelheim, docetaxel + docetaxel (NCT02231164)
- 2025-02-07Results posted on the registry: Taiho Oncology, Inc., Futibatinib + Cisplatin (NCT04093362)
- 2025-02-07Also stopped (terminated): Taiho Oncology, Inc., Futibatinib + Cisplatin (NCT04093362)
- 2025-02-03Also stopped (terminated): Boehringer Ingelheim, Nintedanib + Capecitabine (NCT02780700)
- 2025-02-03Also stopped (terminated): Janssen Research & Development, LLC, Erdafitinib (NCT03587363)
- 2025-01-03Results posted on the registry: Vicore Pharma AB, Drug Drug Interaction (NCT05830799)
- 2025-01-01Results posted on the registry: M.D. Anderson Cancer Center, Infigratinib (NCT04228042)
- 2025-01-01Also stopped (terminated): M.D. Anderson Cancer Center, Infigratinib (NCT04228042)
- 2024-12-10Phase 3 first posted: Sun Yat-sen University, axitinib ± immune checkpoint inhibitors (ICIs), lenvatinib ± ICIs, cabozantinib ± ICIs, sunitinib and pazopanib (NCT06726421)
- 2024-09-19Results posted on the registry: National Cancer Institute (NCI), Erdafitinib (NCT03210714)
- 2024-09-19Results posted on the registry: Incyte Corporation, Pemigatinib + Retifanlimab (NCT04949191)
- 2024-09-19Also stopped (terminated): Incyte Corporation, Pemigatinib + Retifanlimab (NCT04949191)
- 2024-09-19Also stopped (terminated): Taiho Oncology, Inc., Futibatinib and Binimetinib (NCT04965818)
- 2024-08-14Also stopped (terminated): LianBio LLC, Infigratinib (NCT06206278)
- 2024-08-09Results posted on the registry: Ludwig-Maximilians - University of Munich, Pazopanib + Placebo (for Pazopanib) (NCT02207309)
- 2024-08-09Also stopped (terminated): Ludwig-Maximilians - University of Munich, Pazopanib + Placebo (for Pazopanib) (NCT02207309)
- 2024-08-06Results posted on the registry: Incyte Corporation, Pemigatinib (NCT05253807)
- 2024-07-18Phase 3 first posted: Taiho Oncology, Inc., futibatinib + futibatinib, fulvestrant (NCT06506955)
- 2024-06-18Results posted on the registry: National Cancer Institute (NCI), Erdafitinib (NCT06351371)
- 2024-06-18Results posted on the registry: National Cancer Institute (NCI), Erdafitinib (NCT06308822)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision